The Muscle Mag
The firm announced the upcoming launch of a new product line named Nextida, a comprehensive collection of specific compositions designed to promote various health benefits. The initial release will focus on managing glucose levels.
“After extensive research on the collagen molecule, Rousselot is excited to introduce Nextida, offering unique health advantages beyond traditional collagen peptides. Nextida’s key strength is its targeted effectiveness,” stated Jeroen Colpaert, the executive vice president at Rousselot.
The first specific collagen peptide from the Nextida platform to hit the market will be Nextida.GC, aimed at naturally reducing post-meal sugar spikes in healthy individuals.
Global director for health and nutrition, Gaëtan Noiret, highlighted the rising interest in glucose metabolism and blood sugar control, noting the absence of collagen peptide-based solutions in the market.
Scientific studies demonstrating the impact of Nextida.GC on glucose metabolism will be revealed at SupplySide West in Las Vegas in October 2024.
“We will unveil the mechanism of action during Supply Side West,” said Noiret. “In our technical studies, we have observed a significant role of GLP-1 [glucagon-like peptide 1].”
Noiret also mentioned the diverse health benefits provided by Rousselot’s collagen Peptan range, which includes support for sleep, gut health, skin, and joint health.
Metabolic syndrome: ‘the next major pandemic’
Addressing the issue of metabolic syndrome at the Vitafoods symposium, Rick Miller, associate director of specialized nutrition at Mintel, emphasized the importance of recognizing it as a significant public health challenge.
Metabolic syndrome comprises obesity, hypertension, high triglycerides, low HDL cholesterol, and glucose control issues. Miller highlighted data from the American Heart Association indicating a high prevalence of metabolic dysfunction among U.S. residents.
“The Harvard T.H. Chan School of Public Health suggests that lifestyle changes can prevent diabetes, focusing on diet, exercise, and adequate sleep,” he explained.
Miller also mentioned the expanding use of continuous glucose monitoring beyond medical settings, providing valuable insights to consumers despite debates on their accuracy compared to medical-grade devices.
